Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Giuseppe Curigliano, MD, PhD, University of Milano, Milan, Italy, discusses the HER2CLIMB trial (NCT02614794) which investigated tucatinib vs. placebo in combination with capecitabine and trastuzumab in patients with advanced HER2+ breast cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).